Priovant Therapeutics announced Phase 2 BEACON trial results showing 69% of patients treated with brepocitinib 45 mg achieved clear or almost clear skin in cutaneous sarcoidosis, a serious inflammatory skin disease with no FDA-approved treatments. Improvements were seen as early as week 4 and sustained through 16 weeks, with significant quality of life benefits and no serious adverse events reported. These positive results support ongoing Phase 3 BEACON+ trials, with topline data expected in 2028, potentially offering the first targeted therapy for this underserved condition.
The Phase 2 BEACON trial results for brepocitinib in cutaneous sarcoidosis provide context for health sector activity on Pluang as of Nov 11, 2026 01:11 WIB. Among 150 priced US health stocks, 39 rose and 110 fell. Notably, BioNano Genomics Inc (BNGO) gained 12.07%, contrasting with GeneDx Holdings Corp (WGS) which dropped 16.34%, while ACADIA Pharmaceuticals Inc. (ACAD) rose 8.97%, showing a range of investor responses and typical hold times from 21 to 77 days.
As of October 31, 2026, EssilorLuxottica disclosed its total number of shares at 464,247,548 and actual voting rights at 458,376,127 after deducting treasury shares. The company enforces a 31% voting rights cap per shareholder, as outlined in its sta...
EssilorLuxottica disclosed its share capital and voting rights as of October 31, 2026, reporting 464,247,548 shares outstanding and 458,376,127 real voting rights excluding treasury shares. The company applies a 31% cap on voting rights per sharehold...
The global peptide therapeutics market is projected to grow from $112.2 billion in 2026 to $229.32 billion by 2036, at a CAGR of 7.4%. Growth is fueled by expanding use of GLP-1 and incretin therapies, advances in peptide engineering, new oncology ap...
Science 37, a direct-to-patient clinical research site, was named a BioSpace 2027 Best Place to Work, recognized for its innovative culture and commitment to clinical quality. The company’s model brings clinical trials to patients' homes, improving a...
Book Leopard, a new AI software, enables authors and publishers to create professional-quality Amazon book marketing materials in seconds for a one-time fee of $49, drastically reducing costs from over $1,000 and weeks of waiting. The tool generates ...
